Cite
HARVARD Citation
Ruperto, N. et al. (2018). Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Annals of the rheumatic diseases. 77 (12), pp. 1710-1719. [Online].